EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real‐world, retrospective cohort study

Qin-Jie Yang iD, Bi-Xiao Xiang, Mong-Hsiu Song iD, Chien-Yi Yang, Jun-Hao Liang, Yue-Liang Xie iD, Xiao-Cong Zuo

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.4601 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Qin-Jie Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Colistin, Polymyxin B, Acute Kidney Injury, Critical Illness. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polymyxins have re‐emerged as a last‐resort therapeutic option for infections caused by carbapenem‐resistant gram‐negative bacteria. Nephrotoxicity induced by polymyxins is a significant limitation of its use in the clinic. Polymyxin B and colistin sulfate are two widely used active formulations of polymyxins. However, there is a lack of studies conducting a comparative assessment of nephrotoxicity between the two formulations. This study aimed to compare the nephrotoxicity of polymyxin B and colistin sulfate in critically ill patients.

Methods

We conducted a retrospective cohort study among critically ill patients who received intravenous polymyxin B or colistin sulfate for over 48 h from January 2017 to January 2024. The primary outcome was the incidence of acute kidney injury (AKI) associated with polymyxins, and the secondary outcome was 30‐day all‐cause mortality. Additionally, the risk factors of polymyxins‐induced AKI and 30‐day all‐cause mortality were identified by Cox proportional hazard regression analysis.

Results

A total of 473 patients were included in this study. The overall incidence of AKI was significantly higher in patients who received polymyxin B compared to those who received colistin sulfate in the unmatched cohort (20.8% vs. 9.0%, p = 0.002) and in the propensity score matching cohort (21.1% vs. 7.0%, p = 0.004), respectively. However, there was no significant difference in 30‐day all‐cause mortality between the two groups. Polymyxin type, septic shock, and concomitant use of vasopressors were identified as independent risk factors for polymyxin‐induced AKI.

Conclusions

The prevalence of AKI was higher among patients who received polymyxin B compared to those treated with colistin sulfate. However, there was no significant difference in 30‐day all‐cause mortality between the two groups. Further prospective, multicenter studies with larger sample sizes are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColistinPolymyxin BAcute Kidney InjuryCritical IllnessAnti-Bacterial AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedCohort StudiesAdministration, IntravenousIncidenceRisk Factors

Stichwörter der Autor:innen

colistin sulfatecritically ill patientsnephrotoxicitypolymyxin B

Substanzen

ColistinPolymyxin BAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • College of Pharmacy, Zunyi Medical University, Zunyi, Guizhou, China.
  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
  • Department of Pharmacy and Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Qin-Jie Yang, Mong-Hsiu Song, Yue-Liang Xie

Förderung

  • Natural Science Foundation of Hunan Province
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Q. J., Xiang, B. X., Song, M. H., Yang, C. Y., Liang, J. H., Xie, Y. L., & Zuo, X. C. (2024). Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real‐world, retrospective cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4601

Vancouver

Yang QJ, Xiang BX, Song MH, Yang CY, Liang JH, Xie YL, et al. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real‐world, retrospective cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4601

BibTeX
@article{Yang2024,
  author = {Yang, Qin-Jie and Xiang, Bi-Xiao and Song, Mong-Hsiu and Yang, Chien-Yi and Liang, Jun-Hao and Xie, Yue-Liang and Zuo, Xiao-Cong},
  title = {Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real‐world, retrospective cohort study},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.4601}
}
Kostenlos starten →